These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10863318)

  • 21. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity of antiretroviral therapy and implications for drug development.
    Carr A
    Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
    Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
    New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Disorders of lipid and glucose metabolism. Long-term adverse effects of antiretroviral therapy].
    Landauer N; Goebel FD
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():16-8. PubMed ID: 12043065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 30. [HIV-associated lipodystrophy syndrome. Stress for the psyche and heart].
    Mauss S
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():20-5. PubMed ID: 12043066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic complications of antiretroviral therapy.
    Sweet DE
    Top HIV Med; 2005; 13(2):70-4. PubMed ID: 16082057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.
    Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P
    Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
    Maher B; Lloyd J; Wilkins EG; Fraser WD; Back D; Park BK; Pirmohamed M
    Antivir Ther; 2004 Dec; 9(6):879-87. PubMed ID: 15651746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-associated lipodystrophy syndrome.
    Qaqish RB; Fisher E; Rublein J; Wohl DA
    Pharmacotherapy; 2000 Jan; 20(1):13-22. PubMed ID: 10641972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?
    Goulbourne CN; Vaux DJ
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):292-6. PubMed ID: 20074077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy.
    Domingo P; Estrada V; López-Aldeguer J; Villaroya F; Martínez E
    AIDS Rev; 2012; 14(2):112-23. PubMed ID: 22627607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism].
    Schwenk A
    Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.